Genfit S.A.

Genfit S.A. (GNFT) priced its initial public offering on Mar 27, 2019 at $20.32 per ADS, raising $135.1M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $768.8M. Leerink Partners was lead-left underwriter, joined by Barclays, Natixis and Roth Capital and others. Linklaters and Cooley advised the company and Jones Day and Goodwin Procter advised the underwriters.

Genfit S.A. is a late-stage clinical biopharmaceutical company developing drug candidates and diagnostics for metabolic and liver diseases, based on nuclear receptor drug discovery. Its lead candidate, elafibranor, is in a Phase 3 trial for NASH and a Phase 2 trial for primary biliary cholangitis.

Status

IPO

Ticker

GNFT

Exchange

Nasdaq Global Select

Priced

Mar 27, 2019

IPO price

$20.32 per ADS

Raised

$135.1M

Market cap at IPO price

$768.8M

First filed

Feb 27, 2019

Underwriters

Leerink Partners, Barclays, Natixis, Roth Capital and H.C. Wainwright

Company counsel

Linklaters and Cooley

Underwriters' counsel

Jones Day and Goodwin Procter

Sector

Biotech & pharma

Country / state

France

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.